{"id":71406,"date":"2026-07-30T20:48:19","date_gmt":"2026-07-30T12:48:19","guid":{"rendered":"https:\/\/flcube.com\/?p=71406"},"modified":"2026-07-30T20:48:20","modified_gmt":"2026-07-30T12:48:20","slug":"hengrui-pharmaceuticals-her3-targeting-adc-ruzaltatug-rezetecan-receives-nmpa-marketing-application-acceptance-for-egfr-mutant-nsclc-post-tki-progression","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71406","title":{"rendered":"Hengrui Pharmaceuticals&#8217; HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600276:SHA\">SHA: 600276<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that the <strong>marketing authorization application for ruzaltatug rezetecan (SHR-A2009)<\/strong> has been accepted by China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR gene mutations who have progressed following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy<\/strong>. The <strong>HER3-targeting antibody-drug conjugate (ADC)<\/strong> demonstrated <strong>statistically significant progression-free survival (PFS) benefit<\/strong> compared to platinum-based doublet chemotherapy in a pivotal Phase III trial.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application Status<\/strong><\/td><td>Marketing authorization application accepted<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Ruzaltatug rezetecan (SHR-A2009) \u2013 HER3-targeting ADC<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>EGFR-mutant NSCLC post-TKI progression<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Locally advanced or metastatic non-squamous NSCLC with EGFR mutations after TKI failure<\/td><\/tr><tr><td><strong>Trial Basis<\/strong><\/td><td>Randomized, open-label, multicenter Phase III study<\/td><\/tr><tr><td><strong>Primary Endpoint Met<\/strong><\/td><td>Significant PFS improvement vs. platinum-based chemotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-clinical-differentiation\" class=\"wp-block-heading\">Drug Profile &amp; Clinical Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>HER3 (ERBB3)<\/strong>, a member of the EGFR family frequently expressed in EGFR-mutant NSCLC despite TKI resistance<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> <strong>Antibody-drug conjugate (ADC)<\/strong> with optimized linker-payload technology for targeted cytotoxic delivery<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong> Selective binding to HER3-expressing tumor cells followed by internalization and release of cytotoxic payload, overcoming resistance mechanisms that develop during TKI therapy<\/li>\n\n\n\n<li><strong>Clinical Trial Results:<\/strong><\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Statistically significant <strong>progression-free survival (PFS) benefit<\/strong> versus standard platinum-based doublet chemotherapy<\/li>\n\n\n\n<li><strong>Study Design:<\/strong> Randomized controlled, open-label, multicenter Phase III trial<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> EGFR-mutant advanced\/metastatic NSCLC patients who failed prior EGFR TKI therapy<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Addresses critical gap in <strong>post-TKI treatment landscape<\/strong> where current options show limited efficacy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-unmet-need\" class=\"wp-block-heading\">Market Context &amp; Unmet Need<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>EGFR-mutant NSCLC<\/strong> represents approximately <strong>40-50% of Asian NSCLC patients<\/strong> and <strong>10-15% of Western patients<\/strong>, with most eventually developing resistance to <strong>first-, second-, or third-generation EGFR TKIs<\/strong>. After TKI failure, treatment options are limited to <strong>platinum-based chemotherapy<\/strong> with <strong>median PFS of only 4-6 months<\/strong> and significant toxicity burden.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>global EGFR-mutant NSCLC market<\/strong> is valued at <strong>$8-10 billion annually<\/strong>, with substantial commercial opportunity for effective post-TKI therapies. <strong>HER3 expression<\/strong> has been validated as a therapeutic target, with <strong>patritumab deruxtecan<\/strong> (Daiichi Sankyo\/AstraZeneca) showing clinical activity in similar patient populations, establishing proof-of-concept for the target.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Key unmet needs addressed by ruzaltatug rezetecan:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Limited effective options<\/strong> after EGFR TKI resistance develops<\/li>\n\n\n\n<li><strong>Poor prognosis<\/strong> with current standard chemotherapy (median OS ~12-18 months post-TKI)<\/li>\n\n\n\n<li><strong>Need for targeted approaches<\/strong> leveraging persistent HER3 expression in resistant tumors<\/li>\n\n\n\n<li><strong>Opportunity for improved tolerability<\/strong> compared to broad cytotoxic chemotherapy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Hengrui:<\/strong> Represents potential <strong>first-in-class HER3 ADC approval in China<\/strong> and expands oncology portfolio beyond PD-1 inhibitors and small molecules<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> <strong>Phase III data demonstrating PFS superiority<\/strong> over standard of care provides strong regulatory and commercial foundation<\/li>\n\n\n\n<li><strong>Market Timing:<\/strong> Addresses large and growing population of <strong>EGFR TKI-resistant patients<\/strong> in China&#8217;s high-incidence NSCLC market<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Success in Chinese market could support <strong>international regulatory filings<\/strong> and partnership opportunities<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Demonstrates Hengrui&#8217;s <strong>ADC development capabilities<\/strong> across multiple targets and indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-outlook\" class=\"wp-block-heading\">Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> Estimated <strong>25,000-30,000 EGFR-mutant NSCLC patients annually<\/strong> in China progressing after TKI therapy<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Premium pricing expected based on <strong>superior efficacy vs. standard chemotherapy<\/strong> and targeted mechanism<\/li>\n\n\n\n<li><strong>Reimbursement Pathway:<\/strong> Strong candidate for <strong>National Reimbursement Drug List (NRDL)<\/strong> inclusion given significant clinical benefit<\/li>\n\n\n\n<li><strong>Market Penetration:<\/strong> Leverage Hengrui&#8217;s established <strong>oncology sales force<\/strong> and hospital relationships for rapid adoption<\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> Future studies exploring combinations with other targeted agents or immunotherapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps\" class=\"wp-block-heading\">Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Review Timeline:<\/strong> NMPA review expected to conclude within <strong>12-18 months<\/strong> under standard priority review<\/li>\n\n\n\n<li><strong>Manufacturing Scale-up:<\/strong> Commercial production capacity expansion to meet anticipated demand<\/li>\n\n\n\n<li><strong>Physician Education:<\/strong> Comprehensive training programs on <strong>patient selection, dosing, and adverse event management<\/strong><\/li>\n\n\n\n<li><strong>International Development:<\/strong> Preparation for <strong>regulatory submissions in Asia-Pacific markets<\/strong> and potential global partnerships<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approval timelines, commercial launch, and market adoption. Actual results may differ due to risks including regulatory decisions, competitive developments, market acceptance, and clinical practice patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260730_SGUS.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260730_SGUS.\"><\/object><a id=\"wp-block-file--media-11a01e7d-2b59-4743-8947-f3c7106ea269\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260730_SGUS.pdf\">600276_20260730_SGUS<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260730_SGUS.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-11a01e7d-2b59-4743-8947-f3c7106ea269\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the marketing authorization application&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,2586,4228,38,852],"class_list":["post-71406","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-market-approval-filings","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals&#039; HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the marketing authorization application for ruzaltatug rezetecan (SHR-A2009) has been accepted by China&#039;s National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR gene mutations who have progressed following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. The HER3-targeting antibody-drug conjugate (ADC) demonstrated statistically significant progression-free survival (PFS) benefit compared to platinum-based doublet chemotherapy in a pivotal Phase III trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71406\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals&#039; HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the marketing authorization application for ruzaltatug rezetecan (SHR-A2009) has been accepted by China&#039;s National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR gene mutations who have progressed following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. The HER3-targeting antibody-drug conjugate (ADC) demonstrated statistically significant progression-free survival (PFS) benefit compared to platinum-based doublet chemotherapy in a pivotal Phase III trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71406\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T12:48:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-30T12:48:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71406#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71406\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals&#8217; HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression\",\"datePublished\":\"2026-07-30T12:48:19+00:00\",\"dateModified\":\"2026-07-30T12:48:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71406\"},\"wordCount\":669,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"Market approval filings\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71406#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71406\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71406\",\"name\":\"Hengrui Pharmaceuticals' HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-30T12:48:19+00:00\",\"dateModified\":\"2026-07-30T12:48:20+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the marketing authorization application for ruzaltatug rezetecan (SHR-A2009) has been accepted by China's National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR gene mutations who have progressed following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. The HER3-targeting antibody-drug conjugate (ADC) demonstrated statistically significant progression-free survival (PFS) benefit compared to platinum-based doublet chemotherapy in a pivotal Phase III trial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71406#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71406\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71406#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals&#8217; HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals' HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the marketing authorization application for ruzaltatug rezetecan (SHR-A2009) has been accepted by China's National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR gene mutations who have progressed following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. The HER3-targeting antibody-drug conjugate (ADC) demonstrated statistically significant progression-free survival (PFS) benefit compared to platinum-based doublet chemotherapy in a pivotal Phase III trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71406","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals' HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the marketing authorization application for ruzaltatug rezetecan (SHR-A2009) has been accepted by China's National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR gene mutations who have progressed following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. The HER3-targeting antibody-drug conjugate (ADC) demonstrated statistically significant progression-free survival (PFS) benefit compared to platinum-based doublet chemotherapy in a pivotal Phase III trial.","og_url":"https:\/\/flcube.com\/?p=71406","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-30T12:48:19+00:00","article_modified_time":"2026-07-30T12:48:20+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71406#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71406"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals&#8217; HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression","datePublished":"2026-07-30T12:48:19+00:00","dateModified":"2026-07-30T12:48:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71406"},"wordCount":669,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Hengrui Pharmaceuticals","HKG: 1276","Market approval filings","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71406#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71406","url":"https:\/\/flcube.com\/?p=71406","name":"Hengrui Pharmaceuticals' HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-30T12:48:19+00:00","dateModified":"2026-07-30T12:48:20+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the marketing authorization application for ruzaltatug rezetecan (SHR-A2009) has been accepted by China's National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR gene mutations who have progressed following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. The HER3-targeting antibody-drug conjugate (ADC) demonstrated statistically significant progression-free survival (PFS) benefit compared to platinum-based doublet chemotherapy in a pivotal Phase III trial.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71406#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71406"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71406#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals&#8217; HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71406"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71406\/revisions"}],"predecessor-version":[{"id":71408,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71406\/revisions\/71408"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}